Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- US FDA, EMA Hold Monthly Regulatory Working-Level Talks, with Participation of PMDA as Observer
February 27, 2014
- EMA Recommends Approval for Fixed-Dose Combination of Canagliflozin, Metformin
February 27, 2014
- Cabinet OKs Bill to Merge NIBIO, NIHN to Create New Institute
February 26, 2014
- PAFSC’s First Committee Supports Approval of Novel Antiplatelet Agent Prasugrel
February 25, 2014
- Penalty for Lengthy Drug Delivery Talks Will Lift Price Settlement Rates: Minister
February 25, 2014
- MHLW May Take Harsh Action against Novartis over Diovan Raids: Minister Tamura
February 25, 2014
- LDP Closes Discussions on Fee Cuts to Be Imposed on Hospitals, Pharmacies with Low Price Settlement Rates
February 25, 2014
- MHLW to Set Up Complaint Hotline for Hospitals, Pharmacies Upon Introduction of Penalty for Low Price Settlement Rates
February 25, 2014
- Astellas Unit, 12 Others Prequalified for Expedited Product Importation under FDA Pilot Program
February 21, 2014
- PFSB Issues Director Notification Calling for Revision of Package Inserts for Products Including Kiklin, Stivarga
February 20, 2014
- Tokyo Prosecutors Raid Novartis Japan Office over Diovan Ads
February 20, 2014
- Penalty for Lengthy Drug Price Haggling – Interview 1: “It Can’t Be Helped” Says Idaikyo Exec Koyama
February 19, 2014
- MHLW to Form Panel to Combat Counterfeit Drugs
February 19, 2014
- Deputy Director Masuyama of ELD Stresses Need to Establish Separate Guidelines for Different Biosimilars at SRSM Symposium
February 19, 2014
- PAFSC Second Committee to Discuss H5N1 Vaccines on Feb. 28
February 18, 2014
- “Politicians Should Not Intervene” in Dispute Over Rule to Reduce Medical Fees Claimed: Parliamentary Secretary of Health
February 18, 2014
- 34 Firms Win Approval for Diovan Generics, 31 for Preminent Generics towards June Listing
February 17, 2014
- Diet Begins Discussions on 2 Bills Related to Establishment of “Japanese NIH,” Aimed at Commercialization of Innovative New Drugs
February 17, 2014
- Joint Purchasing May Rise as Hospitals with Low Settlement Rates Face Cuts in Fees Claimed: Chuikyo Member
February 17, 2014
- Kaketsuken Makes Another Bid to Fill Unmet Flu Vaccine Quota for 25 Million People
February 14, 2014
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…